Comparing subcutaneous and sublingual ımmunotherapy

Abstract

SLIT and SCIT are both clinically effective in the treatment of respiratory allergic diseases with slight differences in the early phase in terms of onset of clinical efficacy and simultaneous immunological responses. Both SLIT and SCIT induce similar T-cell responses in time, but specific IgG4-blocking antibody responses are more prevalent following SCIT. Further head-to-head studies addressing the preventive effect of monotherapy and the efficacy and immunological responses of nonrelated multiallergen immunotherapy in polysensitized patients are warranted.

Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis

“…[8][9][10]12 As importantly, a review of the recent literature 7,17,22,23 shows that the largest reported clinical studies of SLIT-liquid are less than half the size of our trial. Therefore, our study findings represent a major statement, not only for ragweed but also for SLIT as an entity.…”

Factores involucrados en la adherencia a la inmunoterapia sublingual y subcutánea en pacientes del Servicio de Alergología de una institución de salud en Medellín-Colombia

“…La inmunoterapia (IT) antígeno-específica se usa comúnmente como par-te del tratamiento de enfermedades alérgicas, incluyendo asma alérgica, rinoconjuntivitis alérgica y reacciones sistémicas al veneno de himenópteros. Consiste en la administración de dosis progresivas de extractos de los alergenos involucrados en la afección [7], con una duración de la terapia entre 3 a 5 años [8], y actualmente este es el único tratamiento etiológico para la alergia respiratoria capaz de modificar la historia natural de la enfermedad [9]. La IT específica se ha utilizado por diferentes vías, siendo la subcutánea la más empleada desde el inicio de su aplicación.…”

“…La IT específica se ha utilizado por diferentes vías, siendo la subcutánea la más empleada desde el inicio de su aplicación. También se ha intentado aplicar en mucosas, vía oral, nasal, bronquial, sublingual, pero de estas solo la vía sublingual ha demostrado ser segura y eficaz [7][8][9][10].…”

Impact of allergic rhinitis and specific subcutaneous immunotherapy on peripheral blood basophils of patients sensitized to Dermatophagoides pteronyssinus

“…Specific subcutaneous immunotherapy (SCIT) has been widely reported to show clinical effectiveness in the treatment of allergic rhinitis and asthma [19], providing a long-term remission of allergic symptoms and reducing the development of new sensitization to other allergens [20,21]. The mechanisms by which clinical responses are achieved have been extensively described and include a decrease in basophils and mast cell activation within the affected tissues, induction of T cells anergy, generation of Th1 and Treg cells, decrease of allergen-specific IgE antibody levels, associated with the production of allergen-specific IgG 1 and IgG 4 antibodies (IgG “blocking activity”) and induction of the production of non-inflammatory IgA antibodies by B cells [20,22-24].…”